Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Analysis & Investment Frameworks
Zentalis Pharmaceuticals, Inc. (ZNTL) stock analysis on Invetso. Review Zentalis Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Zentalis Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Zentalis Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $168.00M
- Revenue: $N/A
- ROE: -87.95%
- ROIC: -105.17%
- Dividend Yield: N/A
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Zentalis Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Zentalis Pharmaceuticals, Inc. (ZNTL) across the following frameworks:
- Zentalis Pharmaceuticals, Inc. 10Y Growth Potential
- Zentalis Pharmaceuticals, Inc. Scenario Analysis
- Zentalis Pharmaceuticals, Inc. Risks & Opportunities
- Zentalis Pharmaceuticals, Inc. Economic Moat
- Zentalis Pharmaceuticals, Inc. Business Model
- Zentalis Pharmaceuticals, Inc. Management
- Zentalis Pharmaceuticals, Inc. SWOT Analysis
- Zentalis Pharmaceuticals, Inc. Porter's 5 Forces
- Zentalis Pharmaceuticals, Inc. PESTLE Analysis
- Zentalis Pharmaceuticals, Inc. ESG Analysis